Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD. - Wikidata - thesis-toulmin - TriplyDB

Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.

Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.

http://www.wikidata.org/entity/Q34553334

about

Responsible Translation of Stem Cell Research: An Assessment of Clinical Trial Registration and Publications.ClinicalTrials.gov, stem cells and 'pay-to-participate' clinical studies.Assessment of Safety and Functional Efficacy of Stem Cell-Based Therapeutic Approaches Using Retinal Degenerative Animal Models.New Models for Therapeutic Innovation from Japan.Brief Report: External Beam Radiation Therapy for the Treatment of Human Pluripotent Stem Cell-Derived Teratomas.Regenerative medicine in India: trends and challenges in innovation and regulation.Preclinical Evaluation and Optimization of a Cell Therapy Using Human Cord Blood-Derived Endothelial Colony-Forming Cells for Ischemic Retinopathies.Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial.Unproven stem cell therapy for macular degeneration.The limited application of stem cells in medicine: a review.Endogenous retinal neural stem cell reprogramming for neuronal regeneration.Shifting gears from embryonic to very small embryonic-like stem cells for regenerative medicine.Leveraging social media in the stem cell sector: exploring Twitter's potential as a vehicle for public information campaigns.'No one here's helping me, what do you do?': addressing patient need for support and advice about stem cell treatments.Autologous stem cell therapy for inherited and acquired retinal disease.MicroRNAs: Important Regulators of Induced Pluripotent Stem Cell Generation and Differentiation.Cell-based therapeutic strategies for multiple sclerosis.Induced pluripotent stem cell-based therapy for age-related macular degeneration.Vascular stem/progenitor cells: functions and signaling pathways.Inhibition of mircoRNA-34a Enhances Survival of Human Bone Marrow Mesenchymal Stromal/Stem Cells Under Oxidative Stress.Timeline of events.Ethical and Safety Issues of Stem Cell-Based Therapy.Open for business: a comparative study of websites selling autologous stem cells in Australia and Japan.Regulating the advertising and promotion of stem cell therapies.Pluripotent Stem Cells in Adult Tissues: Struggling To Be Acknowledged Over Two Decades.Exploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular Degeneration.Stem Cell Treatment in Retinal Diseases: Recent Developments.Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions.Allogeneic iPSC-Derived RPE Cell Graft Failure Following Transplantation Into the Subretinal Space in Nonhuman Primates.Preclinical imaging methods for assessing the safety and efficacy of regenerative medicine therapies.Cellular regeneration strategies for macular degeneration: past, present and future.Ex vivo evaluation of intravitreal mesenchymal stromal cell viability using bioluminescence imaging.Retinal ganglion cell neuroprotection by growth factors and exosomes: lessons from mesenchymal stem cells.Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions Stem cell therapy for faecal incontinence: Current state and future perspectives Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration

P2860

Q33659105-055E495B-7B37-41A8-B846-F27B8F1EBE7F Q39443366-A5F84BBA-A8AA-40AD-A25A-89C1EDC64B8C Q41447715-6CF2E8F6-A38F-45AB-A387-CFB90D2F7B66 Q42016113-6E910744-7679-4846-BDF2-19E441876381 Q44917072-F8E094F1-2738-425F-9CB3-DFCEDBB58705 Q45874072-7BF22048-4B0B-4EB5-9E39-6C68C24A542A Q47093712-2ADD58ED-8788-4826-ABEF-3B689EA6249C Q47109230-9B6620B9-28F7-47D5-8339-1394F1995DEE Q47128589-96829A05-BA2F-4B59-B90F-5896EC7942FD Q47134432-57BD0B53-A2EA-4B03-B2B0-7921B903070A Q47137206-E7BBD193-26B6-45AF-9F61-73981ABC65A8 Q47160504-28FBF8C4-A961-4625-A5DD-5C8B31D4BA68 Q47622747-4CFA250C-58C5-4736-87FA-495489CADAFB Q47622771-5266DF2F-2007-448E-9FDB-0C2D717320CF Q47649236-A9E00EAA-B96F-4DBC-85AA-AFC5FB99EE8F Q47837386-A4CAB082-A8B5-4FF7-8875-36508A397C7F Q47885870-4BE468E0-28CC-420A-A6B4-7D0841FE3F09 Q48218214-77A3F87D-07BF-4C4B-978C-120B8DE9703B Q48278651-044DFE4E-3313-4A7A-8DD7-1BAF23D3EDA4 Q48539167-D512D363-C1B1-4B79-9D58-4398B1E364EA Q50030304-F9CAC8B0-722C-4B23-8DEA-631122C1E5EF Q50050571-AF4B3101-290A-4742-AA0B-831948DE46B2 Q50073634-8B41296A-2CF3-4568-9573-4E18701992E7 Q50122051-2C04071F-A57C-4044-8E7F-A49F2ADD38BA Q50501923-499365F6-D83D-4E3F-9A92-37B7FE83074A Q52559837-0F4117D8-3EDB-4867-A1FD-21065B56F326 Q52632524-9E307826-321E-4940-8D5F-506322B049CF Q52686004-D7FF7713-6E8F-4F46-8DB4-C785039E9A1D Q52690801-D1993B2F-24D1-48A8-88A1-37616284D406 Q52737224-430154DC-C439-4904-BB4F-9A33D3E5B188 Q55091758-34A109C9-A499-42C1-87FC-217DFA6EC757 Q55262336-326AA2DE-9A64-422E-BDA1-167EC4317385 Q55415045-C9A6736A-8206-4400-90B4-6B5B8B71F5E7 Q56965233-1A926DC9-D322-4843-9B01-C8386D6AC2D3 Q57126998-8F9763C7-620D-4D01-A967-17CF956F0744 Q58702500-4D4FA757-A724-400F-B692-E78947DDEE3A

P2860

Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.

http://www.wikidata.org/entity/Q34553334

description

2017 nî lūn-bûn

@nan

2017 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մարտին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

name

Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.

@ast

Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.

@en

Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.

@nl

type

label

Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.

@ast

Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.

@en

Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.

@nl

prefLabel

Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.

@ast

Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.

@en

Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.

@nl

P1433

Q34553334-20911DE8-7829-4BF8-A793-64D3E0810530

P1476

Q34553334-C417D1B0-9A50-4815-8936-71301EB8680D

P2093

Q34553334-09EBAD60-83A1-4022-AFB8-EE2338D55C9B

Q34553334-423305AC-846B-4483-9DD0-C04B55A75C35

Q34553334-93214CB6-FC98-4318-9CF4-C46EB7BC8478

Q34553334-99F1860C-6739-4F2F-8D9D-E413BADC811B

Q34553334-9F7EC574-B2BC-42F4-B257-B39F9AD0BB3E

Q34553334-A76F93CC-5454-4898-B2E8-1FD18F0B01A2

Q34553334-A880624F-4BD6-4C89-865F-14A25672D939

Q34553334-B6C863EA-3954-40F5-BAFC-477170119466

Q34553334-CFB35479-E309-4B95-8E3C-25B34EDA0D30

P2860

Q34553334-0EF6C0E0-89EA-45B4-AF25-3318ABE446D9

Q34553334-0F67AA12-F9C0-438E-BBB6-489E34939644

Q34553334-1A1EA07D-3542-4975-BD08-F826093118C1

Q34553334-1F8D6437-3FB1-4693-A7C6-5AD64EB317DE

Q34553334-284F11F7-8629-4E24-995B-7626EC1DA2C7

Q34553334-35DD4C9F-893D-4465-9FD1-3B9DA72201BF

Q34553334-3ED270AF-9D80-4F33-9278-0502F8A2CC42

Q34553334-52D345FD-D0F7-4229-8789-42A701B9B94E

Q34553334-579A2686-F4A6-4E50-B4DA-E05BC56D9249

Q34553334-59AD7C20-8EA9-4D31-A90E-39994FF5B859

P304

Q34553334-9DCA2BC5-D981-47D2-8304-C4585605F4A5

P31

Q34553334-25EFC653-B8F1-4F72-B2E0-6A72F4E950F2

P356

Q34553334-FF2F9A4B-08AD-4749-8468-B241FB1DC702

P407

Q34553334-DCE22580-6677-4FDC-A110-65CA9C8E8367

P433

Q34553334-7FC26955-110F-4BB8-9B6D-968C29A2D24C

P478

Q34553334-E8609BDB-7C41-42A5-A5DD-91275C981582

P50

Q34553334-EA5A5AF5-61AB-45B3-B469-77579885764E

P577

Q34553334-97C20ACB-8631-4A00-9FA2-A285E6810647

P698

Q34553334-63B9FCE6-0F5B-476B-B488-8985BB9AB6F5

P932

Q34553334-DF9D2FC9-5BCA-408B-9867-259F10DFFEF1

P356

P1433

The New England Journal of Medicine

P1476

Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.

@en

P2093

Ajay E Kuriyan

http://www.w3.org/2001/XMLSchema#string

Harry W Flynn

http://www.w3.org/2001/XMLSchema#string

Hemang K Pandya

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Goldberg

http://www.w3.org/2001/XMLSchema#string

Justin H Townsend

http://www.w3.org/2001/XMLSchema#string

M Brandon Parrott

http://www.w3.org/2001/XMLSchema#string

Marianeli Rodriguez

http://www.w3.org/2001/XMLSchema#string

Philip J Rosenfeld

http://www.w3.org/2001/XMLSchema#string

Robert E Leonard

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8

Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies

Ranibizumab for neovascular age-related macular degeneration

Electron microscopic studies on zonular fibers. II. Changes of the zonular fibers after the treatment with collagenase, alpha-chymotrypsin and hyaluronidase.

Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings

Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies.

Unproven stem cell-based interventions & physicians' professional obligations; a qualitative study with medical regulatory authorities in Canada.

From bench to FDA to bedside: US regulatory trends for new stem cell therapies

Stem Cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve diseases: a preliminary report.

Stem Cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve diseases: a case report of improvement in relapsing auto-immune optic neuropathy.

P304

1047-1053

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1609583

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

376

http://www.w3.org/2001/XMLSchema#string

P50

Thomas A. Albini

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28296617

http://www.w3.org/2001/XMLSchema#string

P932

5551890

http://www.w3.org/2001/XMLSchema#string